New combo aims to wipe out leukemia cells in younger patients

NCT ID NCT02158091

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new targeted drug, IPI-145, added to standard chemotherapy and immunotherapy (FCR) for younger adults (18-65) with untreated chronic lymphocytic leukemia (CLL). The goal is to see if the combination is safe and can achieve deep remissions where no cancer cells are detectable. Only 32 participants are enrolled, and the trial is no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IPI-145 (a targeted drug) combined with fludarabine, cyclophosphamide, and rituximab (standard chemotherapy and immunotherapy)
What this could lead to: If this combination works, it could lead to deeper remissions and longer disease control for younger patients with chronic lymphocytic leukemia.
What could go wrong: This is an early-phase trial with only 32 participants, so results may not apply broadly. The added drug IPI-145 could increase side effects like infections or organ toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

Beth Isreal Deaconess Medical Center

Boston, Massachusetts, 02115, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.